GSK/Aspen Deal Indicates Rising Interest In Emerging Markets Beyond ‘BRIC’
This article was originally published in The Pink Sheet Daily
Aspen gains eight specialist medicines and German manufacturing facility from GlaxoSmithKline:
You may also be interested in...
Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data
TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division
Emerging markets present great opportunities, tempered by volatility, vastly different local environments, and ever-changing regulations.